Role of radiotherapy in refractory/relapsed classical Hodgkin lymphoma in the era of targeted therapies and immunotherapy
Relapsed or refractory classical Hodgkin lymphoma (R/R cHL) remains a complex therapeutic challenge despite major advances in systemic treatment.
Relapsed or refractory classical Hodgkin lymphoma (R/R cHL) remains a complex therapeutic challenge despite major advances in systemic treatment.
This claim underlines the continued need for innovative salvage strategies, including radiotherapy, in R/R cHL.
Bizonyítékszint: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.
Kapcsolódó jelek
- Advanced Classical Hodgkin Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group.
- Overcoming PD‑1 Resistance in Relapsed/Refractory Hodgkin Lymphoma
- Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era
- Late cardiopulmonary morbidity in patients with Hodgkin lymphoma: a retrospective nationwide registry study
- Combination of Acimtamig and AlloNK Effective in R/R Classical Hodgkin Lymphoma